[
  {
    "ts": null,
    "headline": "Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders",
    "summary": "Kodiak Sciences uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Read why KOD stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=5818f876ea70b90209b9cd686ce77fbf018b0f585a7a86d113d830306f3a3124",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740341302,
      "headline": "Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders",
      "id": 132859989,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/951515174/image_951515174.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Kodiak Sciences uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Read why KOD stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=5818f876ea70b90209b9cd686ce77fbf018b0f585a7a86d113d830306f3a3124"
    }
  }
]